140 related articles for article (PubMed ID: 38431747)
1. Asparaginase completion among adults including older patients with acute lymphoblastic leukemia treated with a modified DFCI protocol.
Perusini MA; Andrews C; Eshetu AG; Gupta V; Maze D; Yee KWL; Bankar A; Davidson MB; Richard-Carpentier G; Chan SM; Schimmer AD; Sibai J; Alharbi S; Lucero JA; Linn SM; Minden MD; Schuh AC; Sibai H
Leukemia; 2024 Apr; 38(4):912-913. PubMed ID: 38431747
[No Abstract] [Full Text] [Related]
2. Treatment completion, asparaginase completion, and oncologic outcomes among children, adolescents and young adults with acute lymphoblastic leukemia treated with DFCI Consortium Protocols.
Valtis YK; Flamand Y; Shimony S; Place AE; Silverman LB; Vrooman LM; Brunner AM; Sallan SE; Wadleigh M; Stone RM; DeAngelo DJ; Luskin MR
Leukemia; 2024 Mar; 38(3):482-490. PubMed ID: 38177437
[TBL] [Abstract][Full Text] [Related]
3. The effect of asparaginase therapy on methotrexate toxicity and efficacy in children with acute lymphoblastic leukemia.
Kloos RQH; Pieters R; van den Bos C; van Eijkelenburg NKA; de Jonge R; van der Sluis IM
Leuk Lymphoma; 2019 Dec; 60(12):3002-3010. PubMed ID: 31120351
[TBL] [Abstract][Full Text] [Related]
4. PEG-linked asparaginase marketed.
Am J Hosp Pharm; 1994 Jun; 51(11):1382. PubMed ID: 7942872
[No Abstract] [Full Text] [Related]
5. Intensified PEG-L-asparaginase and antimetabolite-based therapy for treatment of higher risk precursor-B acute lymphoblastic leukemia: a report from the Children's Oncology Group.
Salzer WL; Devidas M; Shuster JJ; Wang C; Chauvenet A; Asselin BL; Camitta BM; Kurtzberg J;
J Pediatr Hematol Oncol; 2007 Jun; 29(6):369-75. PubMed ID: 17551397
[TBL] [Abstract][Full Text] [Related]
6. Is asparaginase a critical component in the treatment of acute lymphoblastic leukemia?
Douer D
Best Pract Res Clin Haematol; 2008 Dec; 21(4):647-58. PubMed ID: 19041604
[TBL] [Abstract][Full Text] [Related]
7. Desensitization to pegaspargase in children with acute lymphoblastic leukemia and lymphoblastic lymphoma.
August KJ; Farooki S; Fulbright JM; August A; Portnoy JM; Pommert L; Burke MJ; Guest EM
Pediatr Blood Cancer; 2020 Jan; 67(1):e28021. PubMed ID: 31571395
[TBL] [Abstract][Full Text] [Related]
8. Asparaginase in acute lymphoblastic leukemia.
Kawedia JD; Rytting ME
Clin Lymphoma Myeloma Leuk; 2014 Sep; 14 Suppl():S14-7. PubMed ID: 25486949
[TBL] [Abstract][Full Text] [Related]
9. Detection of anti-asparaginase antibodies during therapy with E.coli asparaginase in children with newly diagnosed acute lymphoblastic leukemia and lymphoma.
Ebeid EN; Kamel MM; Ali BA
J Egypt Natl Canc Inst; 2008 Jun; 20(2):127-33. PubMed ID: 20029468
[TBL] [Abstract][Full Text] [Related]
10. Successful bridging to cell therapy for relapsed/refractory acute lymphoblastic leukaemia with a combination of venetoclax and PEG-asparaginase.
Goursaud L; Berthon C; Quesnel B
Br J Haematol; 2023 Feb; 200(4):e37-e39. PubMed ID: 36470305
[No Abstract] [Full Text] [Related]
11. Use of L-asparaginase in acute lymphoblastic leukemia: recommendations of the Polish Adult Leukemia Group.
Piatkowska-Jakubas B; Krawczyk-Kuliś M; Giebel S; Adamczyk-Cioch M; Czyz A; Lech Marańda E; Paluszewska M; Pałynyczko G; Piszcz J; Hołowiecki J;
Pol Arch Med Wewn; 2008 Nov; 118(11):664-9. PubMed ID: 19140571
[TBL] [Abstract][Full Text] [Related]
12. Cholelithiasis and choledocholithiasis after sequential cytarabine and asparaginase.
Sandoval C; Katz B; Stringel G; Jayabose S; Lebovics E
J Pediatr Hematol Oncol; 2003 Aug; 25(8):637-9. PubMed ID: 12902918
[TBL] [Abstract][Full Text] [Related]
13. Asparaginase-associated myelosuppression and effects on dosing of other chemotherapeutic agents in childhood acute lymphoblastic leukemia.
Merryman R; Stevenson KE; Gostic WJ; Neuberg D; O'Brien J; Sallan SE; Silverman LB
Pediatr Blood Cancer; 2012 Nov; 59(5):925-7. PubMed ID: 22532399
[TBL] [Abstract][Full Text] [Related]
14. Asparaginase use for the treatment of acute lymphoblastic leukemia.
Barba P; Dapena JL; Montesinos P; Rives S
Med Clin (Barc); 2017 Mar; 148(5):225-231. PubMed ID: 28118965
[No Abstract] [Full Text] [Related]
15. L-asparaginase-induced Parotitis in an Elderly Patient with Acute Lymphoblastic Leukemia.
Saburi M; Ogata M; Soga Y; Itani K; Kohno K; Nakayama T
Intern Med; 2020 Jul; 59(14):1745-1748. PubMed ID: 32296003
[TBL] [Abstract][Full Text] [Related]
16. An antithrombin replacement strategy during asparaginase therapy for acute lymphoblastic leukemia is associated with a reduction in thrombotic events.
Farrell K; Fyfe A; Allan J; Tait RC; Leach M
Leuk Lymphoma; 2016 Nov; 57(11):2568-74. PubMed ID: 27078747
[TBL] [Abstract][Full Text] [Related]
17. [Therapeutic alternatives to native L-asparaginase in the treatment of adult acute lymphoblastic leukemia].
Thomas X; Cannas G; Chelghoum Y; Gougounon A
Bull Cancer; 2010 Sep; 97(9):1105-17. PubMed ID: 20693115
[TBL] [Abstract][Full Text] [Related]
18. Management of L-asparaginase induced prothrombotic state in acute lymphoblastic leukemia.
Parma M; Belotti D; Pogliani EM
Haematologica; 1996; 81(2):191. PubMed ID: 8641657
[No Abstract] [Full Text] [Related]
19. Nelarabine, intensive L-asparaginase, and protracted intrathecal therapy for newly diagnosed T-cell acute lymphoblastic leukaemia in children and young adults (ALL-T11): a nationwide, multicenter, phase 2 trial including randomisation in the very high-risk group.
Sato A; Hatta Y; Imai C; Oshima K; Okamoto Y; Deguchi T; Hashii Y; Fukushima T; Hori T; Kiyokawa N; Kato M; Saito S; Anami K; Sakamoto T; Kosaka Y; Suenobu S; Imamura T; Kada A; Saito AM; Manabe A; Kiyoi H; Matsumura I; Koh K; Watanabe A; Miyazaki Y; Horibe K
Lancet Haematol; 2023 Jun; 10(6):e419-e432. PubMed ID: 37167992
[TBL] [Abstract][Full Text] [Related]
20. How I treat the toxicities of pegasparaginase in adults with acute lymphoblastic leukemia.
Aldoss I; Douer D
Blood; 2020 Mar; 135(13):987-995. PubMed ID: 31977001
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
